急性缺血性卒中患者强化与标准降糖治疗的功能结局:SHINE随机临床试验
SHINE随机临床试验纳入1151例急性缺血性卒中伴高血糖患者,随机接受强化静脉胰岛素治疗(目标80-130 mg/dL)或标准皮下胰岛素治疗(目标80-179 mg/dL)最长72小时。90天改良Rankin量表评估的良好功能结局在强化组为20.5%、标准组为21.6%,差异无统计学意义(调整相对风险0.97,95%CI 0.87-1.08,P=0.55)。
要点
- 强化降糖组90天良好功能结局20.5%,标准降糖组21.6%,差异无统计学意义(P=0.55)。
- 强化组严重低血糖发生率为2.6%,仅见于强化组,风险差2.58%(95%CI 1.29%-3.87%)。
- 研究因无效而提前终止,结果不支持在该人群中采用强化降糖治疗。
核心结论
- 急性缺血性卒中伴高血糖患者中,强化与标准降糖治疗最长72小时,90天良好功能结局无显著差异。
- 这些发现不支持在该临床情境中使用强化降糖治疗。
研究设计与样本
- SHINE随机临床试验在美国63个中心开展,2012年4月至2018年8月入组,随访至2018年11月。
- 纳入1151例急性缺血性卒中伴高血糖成人患者(糖尿病者血糖>110 mg/dL,非糖尿病者≥150 mg/dL),卒中发作12小时内入组。
- 患者随机接受强化静脉胰岛素治疗(目标血糖80-130 mg/dL,n=581)或标准皮下胰岛素治疗(目标血糖80-179 mg/dL,n=570),最长72小时。
- 主要疗效结局为90天改良Rankin量表评估的良好功能结局比例,经基线卒中严重程度调整。
主要发现
- 1151例随机患者平均年龄66岁(SD 13.1),女性529例(46%),糖尿病920例(80%),1118例(97%)完成试验。
- 治疗期间强化组平均血糖118 mg/dL(6.6 mmol/L),标准组179 mg/dL(9.9 mmol/L)。
- 90天良好功能结局:强化组119/581例(20.5%)vs 标准组123/570例(21.6%),调整相对风险0.97(95%CI 0.87-1.08),P=0.55;未调整风险差-0.83%(95%CI -5.72%至4.06%)。
- 因低血糖或其他不良事件提前终止治疗:强化组65/581例(11.2%)vs 标准组18/570例(3.2%)。
- 严重低血糖仅见于强化组15/581例(2.6%),风险差2.58%(95%CI 1.29%-3.87%)。
临床怎么用
- 原文结论指出,这些发现不支持在急性缺血性卒中伴高血糖患者中使用强化降糖治疗。
局限性
- 研究因预设中期分析无效标准而提前终止入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hyperglycemia during acute ischemic stroke is common and is associated with worse outcomes. The efficacy of intensive treatment of hyperglycemia in this setting remains unknown. OBJECTIVES: To determine the efficacy of intensive treatment of hyperglycemia during acute ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: The Stroke Hyperglycemia Insulin Network Effort (SHINE) randomized clinical trial included adult patients with hyperglycemia (glucose concentration of >110 mg/dL if had diabetes or ≥150 mg/dL if did not have diabetes) and acute ischemic stroke who were enrolled within 12 hours from stroke onset at 63 US sites between April 2012 and August 2018; follow-up ended in November 2018. The trial included 1151 patients who met eligibility criteria. INTERVENTIONS: Patients were randomized to receive continuous intravenous insulin using a computerized decision support tool (target blood glucose concentration of 80-130 mg/dL [4.4-7.2 mmol/L]; intensive treatment group: n = 581) or insulin on a sliding scale that was administered subcutaneously (target blood glucose concentration of 80-179 mg/dL [4.4-9.9 mmol/L]; standard treatment group: n = 570) for up to 72 hours. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the proportion of patients with a favorable outcome based on the 90-day modified Rankin Scale score (a global stroke disability scale ranging from 0 [no symptoms or completely recovered] to 6 [death]) that was adjusted for baseline stroke severity. RESULTS: Among 1151 patients who were randomized (mean age, 66 years [SD, 13.1 years]; 529 [46%] women, 920 [80%] with diabetes), 1118 (97%) completed the trial. Enrollment was stopped for futility based on prespecified interim analysis criteria. During treatment, the mean blood glucose level was 118 mg/dL (6.6 mmol/L) in the intensive treatment group and 179 mg/dL (9.9 mmol/L) in the standard treatment group. A favorable outcome occurred in 119 of 581 patients (20.5%) in the intensive treatment group and in 123 of 570 patients (21.6%) in the standard treatment group (adjusted relative risk, 0.97 [95% CI, 0.87 to 1.08], P = .55; unadjusted risk difference, -0.83% [95% CI, -5.72% to 4.06%]). Treatment was stopped early for hypoglycemia or other adverse events in 65 of 581 patients (11.2%) in the intensive treatment group and in 18 of 570 patients (3.2%) in the standard treatment group. Severe hypoglycemia occurred only among patients in the intensive treatment group (15/581 [2.6%]; risk difference, 2.58% [95% CI, 1.29% to 3.87%]). CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke and hyperglycemia, treatment with intensive vs standard glucose control for up to 72 hours did not result in a significant difference in favorable functional outcome at 90 days. These findings do not support using intensive glucose control in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01369069.
引用
- Johnston KC, Bruno A, Pauls Q, et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019. PMID: 31334795. doi:10.1001/jama.2019.9346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。